drugset / Trial / NCT07378761

Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

NCT07378761

Phase 2 Not yet recruiting 94 enrolled University Hospital, Montpellier
RandomizedParallel-groupOpen-labelTreatment

Summary

The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period. The trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids.

Timeline

Start
2026-12
Primary completion
2028-09
Completion
2029-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ursodeoxycholic Acid Small molecule 13 mg/kg Oral
Subject Ursodeoxycholic Acid Small molecule 15 mg/kg Oral

Indications